Axovant Sciences (NASDAQ: AXON) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Axovant Sciences to related businesses based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, institutional ownership and valuation.
This table compares Axovant Sciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Axovant Sciences Competitors||-5,441.68%||-162.70%||-35.92%|
Volatility and Risk
Axovant Sciences has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500. Comparatively, Axovant Sciences’ rivals have a beta of 5.81, meaning that their average share price is 481% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Axovant Sciences and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Axovant Sciences Competitors||1134||3426||11925||240||2.67|
Axovant Sciences currently has a consensus target price of $14.75, suggesting a potential upside of 605.74%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.49%. Given Axovant Sciences’ higher possible upside, analysts plainly believe Axovant Sciences is more favorable than its rivals.
Earnings & Valuation
This table compares Axovant Sciences and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Axovant Sciences||N/A||-$180.95 million||-0.91|
|Axovant Sciences Competitors||$290.27 million||$35.99 million||60.32|
Axovant Sciences’ rivals have higher revenue and earnings than Axovant Sciences. Axovant Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
96.9% of Axovant Sciences shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 72.4% of Axovant Sciences shares are held by insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Axovant Sciences rivals beat Axovant Sciences on 7 of the 12 factors compared.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company’s pipeline also includes RVT-103 and RVT-104.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.